Want to see HK:0911 full AI Analyst Report?
Top Page
Qianhai Health Holdings Ltd.
(0911)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$0.49
▲(75.36% Upside)
Action:Downgraded
Date:08/17/26
The score is driven primarily by improving financials and strong balance-sheet stability (minimal leverage and better cash generation), which are partially offset by weak technical momentum (bearish trend signals) and only moderate valuation support given thin profitability.
Positive Factors
Minimal Leverage
Extremely low leverage gives the company substantial financial resilience and reduces interest and refinancing pressure. A conservative capital structure preserves flexibility to fund operations, absorb earnings volatility, and pursue growth without relying heavily on creditors over the next several quarters.
Negative Factors
Very Thin Margins
Very low gross and net margins leave limited protection against pricing pressure, cost increases, or weaker operating conditions. The decline from 2024 also suggests that recent revenue recovery has not yet produced durable operating leverage, making earnings sensitive to execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal Leverage
Extremely low leverage gives the company substantial financial resilience and reduces interest and refinancing pressure. A conservative capital structure preserves flexibility to fund operations, absorb earnings volatility, and pursue growth without relying heavily on creditors over the next several quarters.
Read all positive factors
Qianhai Health Holdings Ltd. (0911) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$79.64M
Dividend Yield121.95%
Average Volume (3M)94.72K
Price to Earnings (P/E)20.0
Beta (1Y)-0.14
Revenue Growth-18.16%
EPS GrowthN/A
CountryHK
Employees19
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.02
Shares Outstanding169,445,000
10 Day Avg. Volume81,220
30 Day Avg. Volume94,721
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.12
Price to Sales (P/S)0.07
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Qianhai Health Holdings Ltd. Business Overview & Revenue Model
Company Description
Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health...
Qianhai Health Holdings Ltd. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
84
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 453.03M | 677.12M | 519.70M | 961.29M | 1.96B | 283.40M |
| Gross Profit | 15.82M | 22.26M | 29.67M | -35.60M | 76.48M | 16.04M |
| EBITDA | 5.49M | 7.39M | 15.64M | -50.23M | -231.24M | 2.06M |
| Net Income | 4.01M | 5.94M | 1.31M | -52.70M | -233.70M | -888.00K |
Balance Sheet | ||||||
| Total Assets | 441.43M | 408.39M | 407.31M | 478.12M | 534.43M | 738.63M |
| Cash, Cash Equivalents and Short-Term Investments | 17.88M | 61.38M | 23.51M | 19.52M | 1.64M | 2.47M |
| Total Debt | 107.00K | 424.00K | 1.03M | 487.00K | 1.19M | 7.83M |
| Total Liabilities | 47.39M | 17.19M | 21.74M | 94.00M | 97.73M | 68.09M |
| Stockholders Equity | 394.05M | 391.20M | 385.57M | 384.11M | 436.70M | 670.53M |
Cash Flow | ||||||
| Free Cash Flow | 34.53M | 38.78M | 4.19M | 857.00K | -5.26M | -44.19M |
| Operating Cash Flow | 34.54M | 38.80M | 4.20M | 857.00K | -5.26M | -44.18M |
| Investing Cash Flow | -3.00K | -14.00K | 246.00K | 17.77M | 12.34M | 46.84M |
| Financing Cash Flow | -324.00K | -648.00K | -712.00K | -743.00K | -7.91M | -16.56M |
Qianhai Health Holdings Ltd. Technical Analysis
Negative
0.28
Price Trends
0.61
Negative
0.65
Negative
0.46
Positive
Market Momentum
-0.03
Positive
38.34
Neutral
19.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0911, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.53, below the 50-day MA of 0.61, and below the 200-day MA of 0.46, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 38.34 is Neutral, neither overbought nor oversold. The STOCH value of 19.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0911.
Qianhai Health Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.93B | 6.49 | 13.26% | 9.23% | -0.47% | -0.40% | |
59 Neutral | HK$79.64M | 20.04 | 1.02% | 121.95% | -18.16% | ― | |
54 Neutral | HK$229.10M | -0.20 | -154.56% | ― | -7.12% | -523.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$219.30M | -6.02 | -8.05% | 2.26% | 12.89% | -2.56% | |
49 Neutral | HK$339.89M | 86.11 | 0.34% | 84.69% | -8.30% | -44.44% | |
43 Neutral | HK$139.08M | -4.57 | -21.66% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:0911
Qianhai Health Holdings Ltd.
0.48
0.19
69.64%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.08
-0.04
-33.33%
HK:0455
Tianda Pharmaceuticals Ltd.
0.10
-0.06
-36.81%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.31
-0.03
-8.82%
HK:1498
PuraPharm Corp. Ltd.
0.26
-0.18
-40.91%
HK:2633
Jacobson Pharma Corporation Limited
0.98
-0.43
-30.69%
Qianhai Health Holdings Ltd. Corporate Events
Qianhai Health’s Interim Profit Holds Up Despite Sharp Revenue Drop
Aug 12, 2026
Qianhai Health Holdings reported unaudited interim revenue of HK$116.76 million for the six months ended 30 June 2026, down sharply from HK$340.85 million a year earlier, with gross profit falling to HK$7.71 million from HK$14.16 million as cost o...
Qianhai Health Sets August Board Meeting for Interim Results and Dividend
Jul 29, 2026
Qianhai Health Holdings Limited has scheduled a board meeting for 12 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026. The board will also consider the publication of these results and whether t...
Qianhai Health Warns of Sharp Profit Drop on Semiconductor Supply Bottlenecks
Jul 24, 2026
Qianhai Health Holdings has warned that profit attributable to its owners for the six months ended 30 June 2026 is expected to fall by about 35% to 45% from a year earlier. The company said the decline stems from lower revenue and gross profit, ma...
Qianhai Health Wins Unanimous Shareholder Backing at AGM
Jun 17, 2026
Qianhai Health Holdings shareholders approved all resolutions at the annual general meeting held on 17 June 2026, with 100% of votes cast in favour of each item. The meeting endorsed the audited financial statements for the year ended 31 December ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.